GSK256066
Sponsors
GlaxoSmithKline
Conditions
Allergic RhinitisAsthmaMild AsthmaPulmonary Disease, Chronic ObstructiveRhinitis, Allergic, SeasonalSeasonal Allergic Rhinitis
Phase 1
Phase 2
Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
CompletedNCT00377728
Start: 2006-03-31End: 2006-05-31Updated: 2015-04-15
Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma
CompletedNCT00380354
Start: 2006-09-30End: 2007-06-30Updated: 2012-06-04
Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
CompletedNCT00430157
Start: 2007-01-31Updated: 2012-06-04
This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge
CompletedNCT00445510
Start: 2006-06-30Target: 24Updated: 2012-06-04
A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis
CompletedNCT00464568
Start: 2007-03-28End: 2007-05-16Updated: 2018-08-20
Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing
CompletedNCT00549744
Start: 2007-11-16End: 2008-08-27Updated: 2017-06-26
Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients
CompletedNCT00549679
Start: 2007-10-04End: 2008-12-15Updated: 2017-07-28
A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
CompletedNCT00612118
Start: 2008-02-29End: 2008-05-31Updated: 2012-06-05
A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)
CompletedNCT00612820
Start: 2008-01-31End: 2008-05-31Updated: 2016-11-03